NO307049B1 - Forbindelse som er <Beta>-adrenergiske agonister, anvendelse derav og farmasøytisk blanding - Google Patents
Forbindelse som er <Beta>-adrenergiske agonister, anvendelse derav og farmasøytisk blandingInfo
- Publication number
- NO307049B1 NO307049B1 NO961887A NO961887A NO307049B1 NO 307049 B1 NO307049 B1 NO 307049B1 NO 961887 A NO961887 A NO 961887A NO 961887 A NO961887 A NO 961887A NO 307049 B1 NO307049 B1 NO 307049B1
- Authority
- NO
- Norway
- Prior art keywords
- beta
- compound
- pharmaceutical composition
- adrenergic agonists
- adrenergic
- Prior art date
Links
- 239000000048 adrenergic agonist Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/73—Unsubstituted amino or imino radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Emergency Medicine (AREA)
- Psychiatry (AREA)
- Neurosurgery (AREA)
- Pulmonology (AREA)
- Child & Adolescent Psychology (AREA)
- Pain & Pain Management (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/IB1995/000344 WO1996035671A1 (en) | 1995-05-10 | 1995-05-10 | β-ADRENERGIC AGONISTS |
| CA002220399A CA2220399A1 (en) | 1995-05-10 | 1995-05-10 | .beta.-adrenergic agonists |
| HU9601240A HUP9601240A1 (en) | 1995-05-10 | 1996-05-09 | Pyridin and pyrimidin derivatives, suitable as beta-adrenerg agonists, pharmaceutical compositions containing the same and their intermediates |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO961887D0 NO961887D0 (no) | 1996-05-09 |
| NO961887L NO961887L (no) | 1996-11-11 |
| NO307049B1 true NO307049B1 (no) | 2000-01-31 |
Family
ID=89993954
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO961887A NO307049B1 (no) | 1995-05-10 | 1996-05-09 | Forbindelse som er <Beta>-adrenergiske agonister, anvendelse derav og farmasøytisk blanding |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US5977124A (pt) |
| EP (1) | EP0824519A1 (pt) |
| JP (1) | JPH11504649A (pt) |
| KR (1) | KR100190259B1 (pt) |
| AU (1) | AU706235B2 (pt) |
| BR (1) | BR9602209A (pt) |
| CA (1) | CA2220399A1 (pt) |
| CO (1) | CO4440567A1 (pt) |
| CZ (1) | CZ132196A3 (pt) |
| FI (1) | FI974172A (pt) |
| HU (1) | HUP9601240A1 (pt) |
| IL (1) | IL118115A0 (pt) |
| MX (1) | MX9708621A (pt) |
| NO (1) | NO307049B1 (pt) |
| NZ (1) | NZ286548A (pt) |
| PL (1) | PL314120A1 (pt) |
| SG (1) | SG43365A1 (pt) |
| TR (1) | TR199600358A2 (pt) |
| WO (1) | WO1996035671A1 (pt) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5981562A (en) * | 1996-01-30 | 1999-11-09 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
| US6008361A (en) * | 1996-04-09 | 1999-12-28 | Pfizer Inc. | Substituted pyridines |
| US6031105A (en) * | 1996-04-09 | 2000-02-29 | Pfizer Inc | Substituted pyridines |
| WO1998021184A1 (en) | 1996-11-14 | 1998-05-22 | Pfizer Inc. | Process for substituted pyridines |
| US6001856A (en) * | 1997-06-13 | 1999-12-14 | Pfizer Inc. | β-adrenergic agonists to reduce a wasting condition |
| EP0920864A1 (en) * | 1997-12-03 | 1999-06-09 | Pfizer Products Inc. | Combination therapy including a specific beta-3 agonist and an anorectic agent |
| US6657063B1 (en) * | 1998-04-30 | 2003-12-02 | Pfizer Inc. | Combinations of β3 agonists and growth hormone secretagogues |
| US6090942A (en) * | 1998-10-15 | 2000-07-18 | Pfizer Inc. | Process and intermediates for a β3 -adrenergic receptor agonist |
| EP1078924B1 (en) * | 1999-07-23 | 2004-10-20 | Pfizer Products Inc. | Intermediates and a process for producing beta-adrenergic receptor agonists |
| EP1218336A2 (en) * | 1999-09-20 | 2002-07-03 | Takeda Chemical Industries, Ltd. | Melanin concentrating hormone antagonist |
| US6451587B1 (en) | 1999-09-29 | 2002-09-17 | Pfizer Inc. | Microbial asymmetric reduction of 2-chloro-1-[-6-(2,5-dimethyl-pyrrol-1-yl)-pyridin-3-yl]-ethanone |
| CN1430603A (zh) * | 2000-04-28 | 2003-07-16 | 旭化成株式会社 | 新型双环化合物 |
| CA2423792A1 (en) | 2000-10-20 | 2002-04-25 | Pfizer Products Inc. | Alpha-aryl ethanolamines and their use as beta-3 adrenergic receptor agonists |
| EP1236723A1 (en) * | 2001-03-01 | 2002-09-04 | Pfizer Products Inc. | Sulfamide derivatives useful as beta3 agonists and pharmaceutical uses thereof |
| MXPA04008298A (es) | 2002-02-27 | 2004-11-26 | Pfizer Prod Inc | Procesos e intermedios utiles en la preparacion de agonistas de receptor beta-3 adrenergico. |
| DOP2003000587A (es) * | 2002-02-27 | 2003-08-30 | Pfizer Prod Inc | AGONISTAS DEL RECEPTOR ß3-ADRENERGICO |
| AU2003209527A1 (en) * | 2002-02-27 | 2003-09-09 | Pfizer Products Inc. | Crystal forms of (r)-2-(2-(4-oxazol-4-yl-phenoxy)-ethylamino)-1-pyridin-3-yl-ethanol |
| US6864268B2 (en) | 2002-02-27 | 2005-03-08 | Pfizer Inc. | β3 adrenergic receptor agonists |
| US20050075323A1 (en) * | 2003-03-05 | 2005-04-07 | Pfizer Inc | Beta3 adrenergic receptor agonists and uses thereof |
| EP1477167A1 (en) * | 2003-05-15 | 2004-11-17 | Pfizer Limited | [(2-hydroxy-2-(4-hydroxy-3-hydroxymethylphenyl)-ethylamino)-propyl] phenyl derivatives as beta2 agonists |
| US7375100B2 (en) | 2003-06-04 | 2008-05-20 | Pfizer Inc | 2-amino-pyridine derivatives useful for the treatment of diseases |
| GB0312832D0 (en) * | 2003-06-04 | 2003-07-09 | Pfizer Ltd | 2-amino-pyridine derivatives useful for the treatment of diseases |
| MXPA06007173A (es) * | 2003-12-23 | 2006-08-23 | Astellas Pharma Inc | Derivados de aminoalcohol. |
| WO2006051373A1 (en) * | 2004-11-12 | 2006-05-18 | Pfizer Limited | Compounds for the treatment of diseases |
| US20090317376A1 (en) | 2005-06-06 | 2009-12-24 | Georgetown University Medical School | Compositions And Methods For Lipo Modeling |
| BRPI0903206E2 (pt) | 2009-09-01 | 2015-07-28 | Da Silva Antonio Carlos Nunes Ett | Unidade processadora e método de processamento de fraldas e absorventes |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4358455A (en) * | 1980-12-23 | 1982-11-09 | Merck & Co., Inc. | Aralkylamindethanol heterocyclic compounds |
| EP0105053B1 (en) * | 1982-10-01 | 1988-01-20 | Merck & Co. Inc. | Aralkylaminoethanol heterocyclic compounds |
| CA1287061C (en) * | 1986-06-27 | 1991-07-30 | Roche Holding Ltd. | Pyridine ethanolamine derivatives |
| GB8703007D0 (en) * | 1987-02-10 | 1987-03-18 | Glaxo Group Ltd | Chemical compounds |
| US5019578A (en) * | 1987-11-27 | 1991-05-28 | Merck & Co., Inc. | β-adrenergic agonists |
| NZ226991A (en) * | 1987-11-27 | 1992-03-26 | Merck & Co Inc | Alpha-heterocyclically-substituted ethanolamines and use as animal growth promotors |
| US5216170A (en) * | 1989-01-26 | 1993-06-01 | Bayer Aktiengesellschaft | (2-aminopropyl) pyridines useful as intermediates |
| GB9209076D0 (en) * | 1992-04-27 | 1992-06-10 | Ici Plc | Chemical compounds |
| JPH08502278A (ja) * | 1992-10-16 | 1996-03-12 | ビイク ネダーラント ベスローテン フェンノートシャップ | 置換されたエタノールアミンエステル |
| EP0677043A1 (en) * | 1992-12-29 | 1995-10-18 | Smithkline Beecham Corporation | Platelet aggregation inhibiting compounds |
| US5451677A (en) * | 1993-02-09 | 1995-09-19 | Merck & Co., Inc. | Substituted phenyl sulfonamides as selective β 3 agonists for the treatment of diabetes and obesity |
| WO1994025427A1 (en) * | 1993-04-26 | 1994-11-10 | Fujisawa Pharmaceutical Co., Ltd. | Ethanolamine derivatives useful for the treatment of gastrointestinal disorders |
| BR9406823A (pt) * | 1993-06-14 | 1996-03-26 | Pfizer | Aminas secundárias e agentes anti-diabéticos e antiobesidade |
| JPH08165276A (ja) * | 1994-12-14 | 1996-06-25 | Dainippon Pharmaceut Co Ltd | ２−アルキルアミノ−１−フェニルエタノール誘導体 |
-
1995
- 1995-05-10 JP JP8533903A patent/JPH11504649A/ja active Pending
- 1995-05-10 MX MX9708621A patent/MX9708621A/es not_active Application Discontinuation
- 1995-05-10 US US08/945,551 patent/US5977124A/en not_active Expired - Fee Related
- 1995-05-10 WO PCT/IB1995/000344 patent/WO1996035671A1/en not_active Application Discontinuation
- 1995-05-10 EP EP95915995A patent/EP0824519A1/en not_active Ceased
- 1995-05-10 CA CA002220399A patent/CA2220399A1/en not_active Abandoned
-
1996
- 1996-05-02 IL IL11811596A patent/IL118115A0/xx unknown
- 1996-05-03 TR TR96/00358A patent/TR199600358A2/xx unknown
- 1996-05-07 CZ CZ961321A patent/CZ132196A3/cs unknown
- 1996-05-07 SG SG1996009751A patent/SG43365A1/en unknown
- 1996-05-08 CO CO96022964A patent/CO4440567A1/es unknown
- 1996-05-08 PL PL96314120A patent/PL314120A1/xx unknown
- 1996-05-09 AU AU52185/96A patent/AU706235B2/en not_active Ceased
- 1996-05-09 HU HU9601240A patent/HUP9601240A1/hu unknown
- 1996-05-09 KR KR1019960015262A patent/KR100190259B1/ko not_active IP Right Cessation
- 1996-05-09 NO NO961887A patent/NO307049B1/no not_active IP Right Cessation
- 1996-05-09 NZ NZ286548A patent/NZ286548A/en unknown
- 1996-05-10 BR BR9602209A patent/BR9602209A/pt active Search and Examination
-
1997
- 1997-11-07 FI FI974172A patent/FI974172A/fi unknown
Also Published As
| Publication number | Publication date |
|---|---|
| FI974172A0 (fi) | 1997-11-07 |
| IL118115A0 (en) | 1996-09-12 |
| JPH11504649A (ja) | 1999-04-27 |
| KR100190259B1 (ko) | 1999-06-01 |
| HUP9601240A1 (en) | 1997-09-29 |
| WO1996035671A1 (en) | 1996-11-14 |
| US5977124A (en) | 1999-11-02 |
| CA2220399A1 (en) | 1996-11-14 |
| AU706235B2 (en) | 1999-06-10 |
| BR9602209A (pt) | 1998-04-07 |
| NZ286548A (en) | 1998-03-25 |
| FI974172A (fi) | 1997-11-07 |
| EP0824519A1 (en) | 1998-02-25 |
| NO961887D0 (no) | 1996-05-09 |
| HU9601240D0 (en) | 1996-07-29 |
| SG43365A1 (en) | 1997-10-17 |
| PL314120A1 (en) | 1996-11-12 |
| MX9708621A (es) | 1998-02-28 |
| TR199600358A2 (tr) | 1996-11-21 |
| KR960041168A (ko) | 1996-12-19 |
| CZ132196A3 (en) | 1997-03-12 |
| CO4440567A1 (es) | 1997-05-07 |
| NO961887L (no) | 1996-11-11 |
| AU5218596A (en) | 1996-11-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO307049B1 (no) | Forbindelse som er <Beta>-adrenergiske agonister, anvendelse derav og farmasøytisk blanding | |
| NO981203D0 (no) | Selektive <beta>3 -adrenergiske agonister | |
| NO307335B1 (no) | Substituerte N-(indol-2-karbonyl)-<beta>-alaninamider, anvendelse derav og farmasøytisk preparat | |
| NO20001409D0 (no) | Karboksamidotiazolderivater, fremgangsmåte for fremstilling derav og farmasøytiske blandinger | |
| NO20006633D0 (no) | Preparat som omfatter <beta>-hydroksy-<beta>-metylsmörsyre og minst én aminosyre, og fremgangsmåter for anvendelse | |
| EE9500064A (et) | Asendatud 1H-imidasoolid, nende valmistamismeetodid ja farmatseutilised kompositsioonid | |
| NO307092B1 (no) | Sordaridin-derivater, anvendelse derav og farmasoeytisk blanding | |
| NO307707B1 (no) | Spiroazabicykliske forbindelser, farmasøytisk preparat inneholdende slike forbindelser og anvendelse derav | |
| NO961432D0 (no) | Benzofiofener og beslektede forbindelser som östrogen-agonister | |
| HUP0100101A3 (en) | Prostaglandin agonists, pharmaceutical compositions comprising thereof and their use | |
| NO973479L (no) | Substituerte heterosykliske forbindelser, fremgangsmåte for fremstilling og farmasöytiske blandinger inneholdende samme | |
| FI960889A (fi) | Naftyyliyhdisteitä, välituotteita, koostumuksia ja menetelmiä | |
| NO993519L (no) | Fenofibrat farmasöytisk blanding som har höy biotilgjengelighet og fremgangsmÕte for fremstilling av den | |
| BR9911871B1 (pt) | derivados de ácido fenoxiacético e composições farmacêuticas contendo os mesmos. | |
| DK0876392T3 (da) | Lacton-derivater af 17.beta.-carboxy, carbothio og amidandrostanforbindelser | |
| DK1006110T3 (da) | Derivater af acylpiperazinylpyrimidiner, fremstilling deraf og anvendelse som lægemidler | |
| PT1112266E (pt) | 4-amino-2-aril-pirimidinas substituidas, sua preparacao, sua utilizacao e composicoes farmaceuticas que as contem. | |
| BR8804191A (pt) | Derivados de avermectina,processo para sua preparacao,composicoes praguicidas e aplicacao | |
| BR9606674B1 (pt) | novo derivado de composto de antraciclina e preparação farmacêutica contendo o mesmo. | |
| NO307784B1 (no) | Polysubstituerte 3-acylamino-5-fenyl-1,4-benzodiazepin-2-on- derivater, farmasøytiske blandinger inneholdende dem og mellomprodukter for fremstilling derav | |
| NO20003662D0 (no) | Syntetiske polysakkarider, fremgangsmÕte for fremstilling derav og farmasøytiske preparater inneholdende slike | |
| ITTO930346A0 (it) | Procedimento per la preparazione di derivati taurocolanici. | |
| DK0755386T3 (da) | Benzamid-derivater, sammensætninger indeholdende nævnte derivat og anvendelse deraf | |
| EE03996B1 (et) | Farmatseutilised kompositsioonid, nende valmistamismeetod ja kasutamine | |
| NO955320D0 (no) | Substituerte 4-fenyltiazolderivater, fremgangsmåte for fremstilling derav og farmasöytiske blandinger som inneholder dem |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM1K | Lapsed by not paying the annual fees |
Free format text: LAPSED IN NOVEMBER 2001 |